Menu Search
Equities

Ligand Pharmaceuticals Inc

LGDN:FRA

Ligand Pharmaceuticals Inc

Actions
  • Price (EUR)94.00
  • Today's Change1.50 / 1.62%
  • Shares traded50.00
  • 1 Year change+59.32%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 15:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Ligand Pharmaceuticals Inc had revenues fall -33.09% from 196.25m to 131.31m, though the company grew net income from a loss of 33.36m to a gain of 52.15m.
Gross margin91.82%
Net profit margin31.57%
Operating margin-14.60%
Return on assets5.19%
Return on equity5.85%
Return on investment5.35%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Ligand Pharmaceuticals Inc fell by 22.05m. However, the company earned 49.58m from its operations for a Cash Flow Margin of 37.75%. In addition the company used 11.68m on investing activities and also paid 59.95m in financing cash flows.
Cash flow per share4.24
Price/Cash flow per share24.51
Book value per share42.82
Tangible book value per share16.92
More ▼

Balance sheet in USDView more

Ligand Pharmaceuticals Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.00%.
Current ratio16.82
Quick ratio15.81
Total debt/total equity0.00002
Total debt/total capital0.00002
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)-12.71
EPS (TTM) vs
TTM 1 year ago		-40.66
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.